May 5, 2014 by Dave Williamson and Michael Douglass2 Great Reasons to Love This Hidden Oligopoly StockCatamaran is seeing a tailwind from Sovaldi.
May 5, 2014 by Dave Williamson and Michael Douglass1 Hot Biotech Stock + 1 Extremely Strange Call = 10% PlungePharmacyclics suffers after one of the weirdest earnings calls ever
May 5, 2014 by Dave Williamson and Michael DouglassThis Game Changing Mega Merger Isn't Dead YeatWhy Pfizer can't quit AstraZeneca.
May 5, 2014 by Dave Williamson and Michael Douglass30 Billion Potential Reasons to Love Merck & Co., Inc.Merck is about to transform itself and raise a ton of money in the process
May 4, 2014 by Dave Williamson and Michael Douglass1 Biotech's Earnings the Market Got Completely WrongCelgene's earnings disappointment was a case of unbridled enthusiasm meeting reality.
May 4, 2014 by Dave Williamson and Michael Douglass1 Pipeline Stocked Full of PromiseSanofi pipeline's is stocked with potential blockbusters. Can they deliver?
May 3, 2014 by Dave Williamson and Michael Douglass1 Pipeline All Investors Need to KnowMerck's pipeline, headlined by immuno-oncology, demands investor attention
May 3, 2014 by Dave Williamson and Michael DouglassDid This Lightning-Rod Drug Go Too Far?Express Scripts and Gilead are at odds over hepatitis C cure Sovaldi's pricing.
May 3, 2014 by Dave Williamson and Michael DouglassNovartis Earnings: What Investors Need to KnowNovartis earnings were solid, but investors should look to the future
May 3, 2014 by Dave Williamson and Michael DouglassWhy the Market Is Wrong About Biogen Idec Inc.Biogen has sold off since its earnings report last week, but this could be another classic case of market overreaction.
May 3, 2014 by Dave Williamson and Michael DouglassEli Lilly Earnings: What Investors Need to KnowEli Lilly earnings may have disappointed some, but the company isn't standing still.
May 3, 2014 by Dave Williamson and Michael DouglassA White Knight Riding to the Rescue?If Allergan is looking for its own acquirer, who makes the best strategic fit?
May 3, 2014 by Dave Williamson and Michael DouglassMerck Earnings: What Investors Need to KnowMerck's earnings were mixed for the first quarter.
Apr 30, 2014 by Dave Williamson and Michael DouglassDividend Stock Sanofi's Earnings Made EasySanofi earnings came in a little light -- what should investors watch for going forward?
Apr 25, 2014 by Dave WilliamsonA $13-Billion Neighborhood TakeoverZimmer Holdings, Inc goes 2.5 miles and becomes a dominant player.
Apr 23, 2014 by Dave Williamson1 Critical Catalyst for Intuitive Surgical InvestorsThe slide continues, but what does the future hold for this popular stock?
Apr 20, 2014 by Dave Williamson and Michael DouglassMarijuana Stocks: 2 More to AvoidPot shots at pot stocks.
Apr 20, 2014 by Dave Williamson and Michael DouglassJohnson & Johnson's Earnings Made EasyJNJ Earnings beat expectations, but is trouble lurking beneath the headlines?
Apr 15, 2014 by Dave Williamson and Michael DouglassBiotech Bubble Bust: 2 Ways to WinWhy Gilead and Biogen are the best ways to play the biotech meltdown.
Apr 15, 2014 by Dave Williamson and Michael DouglassWhy Investors Need to Watch Sarepta Therapeutics Inc.The FDA will soon decide the path forward for Sarepta's muscular dystrophy drug.
